EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study

Wei Li iD, Jinghui Tong iD, Xiaoxiao Gao, Hu Deng, Zezhi Li iD, Junhong Zhu iD, Jiahong Liu iD, Yanchi Zhang iD, Dengtang Liu iD, Xiaobin Zhang, Jianping Tang iD, Yuxiu Sui iD und 14 weitere

Alpha Psychiatry · 22.04.2026 · 27 (2)

DOI: 10.31083/ap39454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alpha Psychiatry, online erschienen am 22.04.2026. Verfasst von Wei Li und 25 weiteren Autor:innen. Beteiligte Einrichtung: Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting injectable (LAI) antipsychotics improve adherence and promote long-term recovery in schizophrenia spectrum disorders (SSD). Risperidone Microspheres for Injection (II) (RMI-II), a novel LAI formulation, offers rapid symptom control with a 2-week dosing interval. However, real-world evidence regarding its efficacy and safety remains limited.

Methods

A prospective, single-arm, multicenter study was conducted across 15 Chinese research centers. Eligible patients (n = 228) met DSM-5 criteria for SSD, had a Positive and Negative Syndrome Scale (PANSS) total score ≥70, and were followed for 12 weeks. Patients received RMI-II (25–50 mg/2 weeks) via intramuscular injection.

Results

Among 228 patients (50.88% male, mean age [37.00 ± 12.82] years) receiving RMI-II, the PANSS total score decreased significantly by 14.02 (3.22, 24.85) at week 2 (p < 0.001) and 38.28 (19.02, 51.34) at week 12 (p < 0.001). At week 2, 37.1% patients achieved clinical response (defined as ≥20% reduction in PANSS total score), and this proportion increased to 83.7% by week 12. By the end of the 12-week treatment, the clinical remission rate (defined as scores ≤3 on PANSS items P1, P2, P3, N1, N4, N6, G5, and G9) was 68.9%. The Clinical Global Impression–Severity Scale score improved from a baseline moderate-to-severe level 5.0 (5.0, 6.0) to a mild-to-moderate level 3.0 (2.0, 4.0). Adverse events occurred in 15.35% of patients, with hyperprolactinemia (1.3%) and extrapyramidal symptoms (1.3%) being most common.

Conclusions

RMI-II appeared to be effective and well-tolerated in reducing acute psychotic symptoms. These findings suggest it may represent an additional therapeutic option for SSD. Clinical Trial Registration: No: ChiCTR2200066865, 20 December 2022, https://www.chictr.org.cn/showproj.html?proj=183302.

Schlagwörter

Stichwörter der Autor:innen

long-acting injectable antipsychoticspositive and negative syndrome scalereal-world studyrisperidone microspheresschizophrenia spectrum disorders

Autor:innen und Institutionen

  • Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, 100096 Beijing, China.
  • The Affiliated Brain Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and The Ministry of Education of China, Guangzhou Medical University, 510370 Guang…
  • The Affiliated Wuhan Mental Health Center of Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China.
  • Zhejiang Provincial Clinical Research Center for Mental Health, The Affiliated Kangning Hospital of Wenzhou Medical University, 325007 Wenzhou, Zhejiang, China.
  • Department of Psychology, The Sixth Hospital of Changchun, 130052 Changchun, Jilin, China.
  • Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, 200030 Shanghai, China.

ORCID-Profile: Wei Li, Jinghui Tong, Zezhi Li, Junhong Zhu, Jiahong Liu, Yanchi Zhang, Dengtang Liu, Jianping Tang, Yuxiu Sui, Hezeng Yang, Yunshu Zhang, Chao Li, Baoping Xing, Yi Wang, Yunlong Tan

Zitieren

APA

Li, W., Tong, J., Gao, X., Deng, H., Li, Z., Zhu, J., Liu, J., Zhang, Y., Liu, D., Zhang, X., Tang, J., Sui, Y., Yang, H., Zhang, Y., Li, C., Zhou, X., Xing, B., Wang, Y., Song, J., …, & Tan, Y. (2026). Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study. Alpha Psychiatry, 27(2). https://doi.org/10.31083/ap39454

Vancouver

Li W, Tong J, Gao X, Deng H, Li Z, Zhu J, et al. Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study. Alpha Psychiatry. 2026;27(2). doi:10.31083/ap39454

BibTeX
@article{Li2026,
  author = {Li, Wei and Tong, Jinghui and Gao, Xiaoxiao and Deng, Hu and Li, Zezhi and Zhu, Junhong and Liu, Jiahong and Zhang, Yanchi and Liu, Dengtang and Zhang, Xiaobin and Tang, Jianping and Sui, Yuxiu and Yang, Hezeng and Zhang, Yunshu and Li, Chao and Zhou, Xuhui and Xing, Baoping and Wang, Yi and Song, Jiaqi and Zhang, Rongzhen and Shen, Yang and Song, Yanying and Zhou, Yanfang and Pan, Shujuan and Zheng, Wei and Tan, Yunlong},
  title = {Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study},
  journal = {Alpha Psychiatry},
  year = {2026},
  volume = {27},
  number = {2},
  doi = {10.31083/ap39454}
}
Kostenlos starten →